BioSpace News Archive

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2024 second quarter results for the period ended March 31, 2024.

FDA Grants Priority Review to Merck’s Application for KEYTRUDA ® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma.

HuidaGene Therapeutics and Synthego Corporation (“Synthego”), a leading provider of innovative CRISPR solutions for developing cell and gene therapies, proudly announce a partnered licensing agreement for the high-fidelity Cas12 CRISPR nuclease (hfCas12Max).

Virpax ® Pharmaceuticals, Inc. today announced that it will be presenting at the upcoming Bio International Convention in San Diego on Monday, June 3rd at 4:00 p.m. PT. Gerald W. Bruce, CEO of Virpax, will deliver the corporate presentation.

BioNTech SE and the Coalition for Epidemic Preparedness Innovations are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.

KALA BIO, Inc. announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET.

Bluejay Therapeutics announced that the European Medicines Agency has issued a positive opinion on the Company’s application for orphan designation for BJT-778 for the treatment of chronic hepatitis D.

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for its Phase 1/2 clinical trial of SPG302 for the treatment of people with Amyotrophic Lateral Sclerosis.